Latest Proof Of Concept News

Beonic has launched its in-house Vision platform across four countries while delivering a profitable first quarter, with EBITDA of A$853,000 and an 83.0% gross margin. The stronger operating result came alongside weaker total revenue, negative operating cash flow and only 1.7 quarters of estimated funding.

Iltani Resources reported 59 substantial silver-equivalent intercepts at its Orient project during a busy September quarter, including several exceptionally high-grade zones. The explorer also completed a $4.6 million placement after quarter-end, giving its next drilling and metallurgical work a stronger funding base, while adding dilution and options to the capital structure.

SRJ Technologies has won a US$301,000 purchase order for its BoltEx flange integrity technology, marking its first significant deployment in the Middle East. The full contract value is scheduled to be paid before delivery to the end operator, giving the order unusually strong payment protection.

ION Video has moved its video technology into a series of externally funded and independently assessed validation programs, including an AWS proof of concept and a potential Nordic data centre trial worth at least A$1 million. The company ended September with A$3.522 million in cash, but remains pre-revenue and expects higher spending as commercialisation efforts expand.

INOVIQ will restart its EXO-OC ovarian cancer program through a staged optimisation and verification process after an independent review found sample collection and handling were the main sources of variability. The company is targeting US laboratory-developed test readiness in the first half of 2028, while a leadership change adds another moving part.

PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.

Gratifii has put its rebuilt Connect+ Marketplace in front of Qantas, Woolworths MarketPlus and Blackhawk Network, opening distribution channels that reach millions of loyalty members. The commercial momentum came as quarterly cash receipts fell 16.5% and available funding stood at roughly 2.5 quarters.

AoFrio’s nine-month revenue fell 20% to NZ$50.3 million as motor sales plunged, while EBITDA dropped to NZ$0.8 million. The NZX-listed refrigeration technology company is relying on new US bottler orders, Food Retail expansion and its IoT platform to support a more profitable 2027.

Antimony Resources has moved its Tecomatlán plant into its first plant-scale antimony concentrate campaign, but reported only 0.9 quarters of funding at September’s cash burn. The campaign could provide the company’s first operating proof point, while also sharpening the need for additional financing or commercial revenue.

Archer Materials has moved its IonQ relationship into early commercial activity and advanced its Biochip towards external testing, but its graphene spin qubit demonstration is taking longer than expected. The company ended September with $A13.0 million in cash and an estimated 4.68 quarters of funding at its quarterly operating burn.

Resonance Health has secured an oversubscribed $6.0 million placement to fund MRI endpoint expansion, new TrialsWest sites and development of its non-invasive liver fibrosis device. The raise lifts pro forma net cash to $7.9 million, but the most consequential project remains an investigational technology backed by a small preliminary dataset.

Energy Technologies has outlined two signed commercial arrangements for its Cogenic laser display technology, including a SYNCH purchasing framework worth up to US$10 million and a 5% royalty licence with Amalgamated Vision. The opportunity is meaningful, but the SYNCH arrangement carries no minimum order commitment and still depends on product specifications, acceptance and purchase orders.